Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent
This study is currently recruiting participants.
(see Contacts and Locations)
Verified April 2013 by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Sponsor:
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Information provided by (Responsible Party):
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier:
NCT01771562
First received: January 16, 2013
Last updated: April 3, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The advent of highly active antiretroviral treatment has resulted in the survival into adolescence of an increasing proportion of infants and children with perinatal HIV infection in Senegal. However, the transformation of HIV into a chronic disease needing lifelong antiretroviral treatment (ART) raises new challenges, among others related to a disturbance of glucose metabolism, lipid abnormalities, in addition to the potential effects on children's growth and puberty. Little is known on nutritional and metabolic changes in HIV-infected children on ART in Africa, while implementation of the latest WHO recommendations should eventually lead to an increase in the number of children on ART in this region. Moreover, bio-clinical evolution of untreated children is poorly documented in the African context. It therefore urgently needed to institute a cohort study to evaluate, in the long term, the impact of HIV infection and/or ART on nutritional and metabolic disorders and to characterize the risk factors of their occurrence in children and adolescents infected as they move through adolescent into adulthood.
| Condition |
|---|
|
HIV-1 |
| Study Type: | Observational [Patient Registry] |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Target Follow-Up Duration: | 3 Years |
| Official Title: | Assessment of Risk Factors of Nutritional and Metabolic Disorders in Children and Adolescent Receiving or Not Antiretroviral Treatment : Growing up With HIV in Senegal |
Resource links provided by NLM:
Genetic and Rare Diseases Information Center resources:
Children's Interstitial Lung Disease
Lipodystrophy
U.S. FDA Resources
Further study details as provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):
Primary Outcome Measures:
- Prevalence of delayed growth [ Time Frame: Baseline ] [ Designated as safety issue: No ]Delayed growth is defined by height for age < -2 z-scores, wasting (%) by weight-for height < -2 z-scores and/or BMI-age < -2 z-scores
- Prevalence of delayed puberty [ Time Frame: Baseline ] [ Designated as safety issue: No ]Delayed puberty is assessed by age of entry into puberty and the age of transition to different Tanner staging
- Prevalence of lipodystrophy [ Time Frame: Baseline ] [ Designated as safety issue: No ]Lipodystrophy (lipoatrophy, lipohypertrophy, combined forms) is defined by direct observation and by joint analysis of anthropometric measures associated with fat tissue index and lean tissue index measured by electrical bio-impedancemetry
- Prevalence of blood lipids ans glucose abnormalities [ Time Frame: Baseline ] [ Designated as safety issue: No ]Measurement of blood glucose, total cholesterol, HDL, LDL and triglycerides
- Incidence of delayed growth [ Time Frame: Annually for 3 years from the anniversary date of the study ] [ Designated as safety issue: No ]Delayed growth is defined by height for age < -2 z-scores, wasting (%) by weight-for height < -2 z-scores and/or BMI-age < -2 z-scores
- Incidence of delayed puberty [ Time Frame: Annually for 3 years from the anniversary date of the study ] [ Designated as safety issue: No ]Assessed by age of entry into puberty and the age of transition to a different Tanner stage
- Incidence of lipodystrophy [ Time Frame: Annually for 3 years from the anniversary date of the study ] [ Designated as safety issue: No ]defined by direct observation and by joint analysis of anthropometric measures associated with changes in fat tissue index and lean tissue index measured by electrical bio-impedancemetry
- Incidence of blood lipid and glucose abnormalities [ Time Frame: Annually for 3 years from the anniversary date of the study ] [ Designated as safety issue: No ]Repeated measurement of blood glucose, total cholesterol, HDL, LDL and triglycerides
Biospecimen Retention: Samples With DNA
Plasma, blood cells and urine samples to be retained
| Estimated Enrollment: | 400 |
| Study Start Date: | April 2013 |
| Estimated Study Completion Date: | April 2016 |
| Estimated Primary Completion Date: | April 2016 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 2 Years to 15 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
HIV-1 infected individuals age between 2 ans 16 years
Criteria
Inclusion Criteria:
- HIV-1 infection
- Age equal or above 2 years and bellow 16 years
- Follow-up in the participating site
- Informed consent signed by at least on of the parents or legal guardian who is aware of the child's HIV status
Exclusion Criteria:
- HIV-2 or HIV-1+2 infection
- children represented by a legal guardian who is not informed about the child's HIV status
- Unable to comply with study requirements or procedures according to the investigator's opinion
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01771562
Please refer to this study by its ClinicalTrials.gov identifier: NCT01771562
Locations
| Senegal | |
| Hôpital d'enfant Albert Royer | Recruiting |
| Dakar, Senegal | |
| Contact: Haby Sy Signate, MD +221 33 825 03 08 habysignate@yahoo.fr | |
| Sub-Investigator: Aminata Diack Mbaye, MD | |
| Sub-Investigator: Ramatoulaye Guéye, MD | |
| Sub-Investigator: Hélène Dior Mbodj, MD | |
| Sub-Investigator: Ndeye Fatou Diallo, MD | |
| Hôpital Roi Baudoin | Not yet recruiting |
| Guédiawaye, Senegal | |
| Contact: Ngaye Mbaye, MD +221 33877 85 15 ngagne@orange.fr | |
| Sub-Investigator: Baly Ouattara, MD | |
| Sub-Investigator: Maty Diouf Sakho, MD | |
Sponsors and Collaborators
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Investigators
| Principal Investigator: | Philippe Msellati, MD | IRD : French Research Institute for Development | |
| Principal Investigator: | Haby Sy Signate, MD | Hôpital d'Enfant Albert Royer, Dakar, Senegal | |
| Principal Investigator: | Ngagne Mbaye, MD | Hôpital Roi Baudoin, Guédiawaye, Senegal |
More Information
Additional Information:
No publications provided
| Responsible Party: | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) |
| ClinicalTrials.gov Identifier: | NCT01771562 History of Changes |
| Other Study ID Numbers: | ANRS 12279 MAGGSEN |
| Study First Received: | January 16, 2013 |
| Last Updated: | April 3, 2013 |
| Health Authority: | Senegal: Ministry of Health and Social Action |
Keywords provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):
|
HIV-1 Child Adolescent Growth |
Lipodystrophy ARV treatment Senegal |
ClinicalTrials.gov processed this record on February 27, 2015